21 April 2026 Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial Ultomiris delivered rapid reduction in proteinuria as early as week 10 Results show potential for terminal C5 complement inhibition with Ultomiris as a disease-modifying...
20 April 2026 Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Third positive pivotal Phase III clinical trial of AstraZeneca's IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a...
2 April 2026 Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial Imfinzi plus Imjudo combined with lenvatinib and transarterial chemoembolisation (TACE) showed trend...
This announcement contains inside information 31 March 2026 Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia MULBERRY randomised, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and clinically meaningful improvement in bone health in treatment-na•ve paediatric...
This announcement contains inside information 27 March 2026 Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive...